To evaluate the effectiveness and safety of transurethral blue laser vaporization resection for the treatment of benign prostatic hyperplasia (BPH). The Department of Urology at Xianyang Central Hospital (Fan Zhenwei, Cheng Haifeng, Du Quan, Liu Guoxiong, Li Nan, Qiao Ximin, Xu Xiaofeng) conducted a retrospective analysis of the clinical data of 100 BPH patients who underwent transurethral blue laser vaporization surgery from May to September 2022. The team observed and analyzed the surgical time, postoperative hemoglobin decrease, bladder flushing duration, postoperative indwelling catheterization time, and postoperative hospital stay Surgical complications, as well as changes in relevant indicators such as the International Prostate Symptom Score (IPSS), Quality of Life Rating Scale (QoL), Maximum Urinary Flow Rate (Qmax), and Bladder Residual Urinary Volume (PVR) before and 3 months after surgery.

Conclusion: The blue laser semiconductor therapy machine has satisfactory tissue vaporization and hemostatic effects. Transurethral blue laser vaporization of the prostate is a new safe and efficient surgical method for treating BPH.

Detailed content of the article